Track 1. Biomarker:

A biomarker is a biological characteristic that is objectively measured and evaluated as an indicator of normal biological or pathological processes, or a response to a therapeutic intervention.

Track 2. Toxicology:

Toxicology is a field of science that helps us understand the harmful effects that chemicals, substances, or situations, can have on people, animals, and the environment. Biomarkers have been used in medicine and toxicology for many years to assist in diagnosing and staging disease

Track 3. Microbiome:

Microbiome is a term that describes the genome of all the microorganisms, symbiotic and pathogenic, living in and on all vertebrates. A microbiome is the community of micro-organisms living together in a particular habitat.

Track 4. Alternatives to Animal Testing:

Alternatives to Animal testing include sophisticated tests using human cells and tissues  also known as in vitro methods, advanced computer-modelling techniques often referred to as in silico models, and studies with human volunteers.

Track 5. Hormones and Breast Cancer:

Hormonal influences that affect growth of the mammary gland increase the risk of breast cancer. Hormone therapy can reach cancer cells almost anywhere in the body and not just in the breast. It's recommended for women with tumors that are hormone receptor-positive. It does not help women whose tumors don't have hormone receptors.

Track 6. DNA and Childhood Asthma Risk:

Childhood asthma represents a heterogeneous challenging disease, in particular in its severe forms. The identification of different asthma phenotypes has stimulated research in underlying molecular mechanisms, such as the endotypes, and paved the way to the search for related specific biomarkers, which may guide diagnosis, management, and predict response to treatment.

Track 7. Genomic Biomarkers:

Genomic biomarkers are variants in the DNA code that alone or in combination are associated with disease susceptibility, disease expression and disease. Genomic biomarker may have good accuracy and reproducibility across a range of independent validation data sets.

Track 8. Cardiac Biomarkers:

Biomarkers have an essential role in diagnosis, risk stratification, guiding management and clinical decision making in the setting of patients presenting with signs and symptoms of MI.  Cardiac enzymes also known as cardiac biomarkers which includes myoglobin, troponin and creatine kinase. Historically, lactate dehydrogenase or LDH.

Track 9. Immunological Biomarkers:

Biomarkers in immunologic biomarkers can be either prognostic or predictive. In many circumstances they are the most investigated prognostic immunologic marker is the occurrence of infiltration of a tumor by immune cells. The immune system plays a special role in biomarker discovery since it interacts with all other systems in the human body and immune biomarkers.

Track 10. Pharmaceutical Sciences:

Biomarkers are important tools in drug development and are used throughout pharmaceutical research. In the field of drug discovery and development, the process of identifying and validating disease specific biomarkers has been quite challenging. Recent advances in multiple approaches (genomics, transcriptomics, proteomics, metabolomics, cytometry and imaging) in combination with bioinformatics and biostatistics have made it possible to accelerate the discovery and development of specific biomarkers for complex chronic diseases.

The global biomarkers market is estimated to reach USD 53.34 Billion by 2021 from USD 27.95 Billion in 2016, at a CAGR of 13.8% from 2016 to 2021. Growth in the global biomarkers industry is mainly driven by factors such as increasing diagnostic applications of biomarkers, increasing R&D funding for pharma and biotech companies, increasing number of CROs and low cost of clinical trials in developing countries, the high prevalence of cancer, and new initiatives for research. On the other hand, high capital investments and low cost-benefit ratio, poorly suited regulatory and reimbursement systems, and technical issues related to sample collection and storage are the major factors restraining the growth of this market. Based on type, the biomarkers market is segmented into safety, efficacy, and validation biomarkers. The efficacy biomarkers segment is further classified into predictive, surrogate, pharmacodynamic, and prognostic biomarkers.